MORGAN DONNELLAN DENSFORD: Open Payments
NPI 1427724210 · OLNEY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$830 in 43 payments from 13 companies in 2025. Trend: 2023 $516 · 2024 $1,125 · 2025 $830
Food & beverage: $830
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $180 |
| GENZYME CORPORATION | 5 | $108 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $95 |
| Regeneron Healthcare Solutions, Inc. | 4 | $82 |
| QOL Medical, LLC | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Ardelyx, Inc. | 3 | $50 |
| Pharmacosmos Therapeutics Inc. | 1 | $48 |
| Celltrion USA Inc. | 2 | $39 |
| Digestive Care, Inc. | 1 | $38 |
Products named: DUPIXENT, XIFAXAN, Sucraid, SKYRIZI, RINVOQ, EOHILIA, IBSRELA, MONOFERRIC.
Industry payments across MD — which companies pay providers there.
